DrugPatentWatch Database Preview

Drugs in Development Information for SM04690

Email this page to a colleague

« Back to Dashboard

What is the drug development status for SM04690?

SM04690 is an investigational drug.

There have been 10 clinical trials for SM04690. The most recent clinical trial was a Phase 1 trial, which was initiated on May 1^st 2019.

The most common disease conditions in clinical trials are Osteoarthritis, Osteoarthritis, Knee, and Spinal Diseases. The leading clinical trial sponsors are Samumed LLC and [disabled in preview].

There are ten US patents protecting this investigational drug and eighty international patents.

Summary for SM04690

US Patents	10
International Patents	80
US Patent Applications	24
WIPO Patent Applications	6
Japanese Patent Applications	6
Clinical Trial Progress	Phase 1 (2019-05-01)
Vendors	19

Recent Clinical Trials for SM04690

Title	Sponsor	Phase
Drug-Drug Interaction Study of Lorecivivint and Triamcinolone Acetonide in Healthy Volunteers	Samumed LLC	Phase 1
Extension Study Evaluating the Safety and Efficacy of a Second Year of Use of Lorecivivint in Subjects With Osteoarthritis of the Knee	Samumed LLC	Phase 3
A Study Utilizing Patient-Reported Outcomes to Evaluate the Safety and Efficacy of Lorecivivint (SM04690) for the Treatment of Moderately to Severely Symptomatic Knee Osteaoarthritis	Samumed LLC	Phase 3

See all SM04690 clinical trials

Clinical Trial Summary for SM04690

Top disease conditions for SM04690

Top clinical trial sponsors for SM04690

See all SM04690 clinical trials

US Patents for SM04690

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
SM04690		Process for preparing N-(5-(3-(7-(3-fluorophenyl)-3H-imidazo [4,5-C]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide	Samumed, LLC (San Diego, CA)
SM04690		Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof	Samumed, LLC (San Diego, CA)
SM04690		Treatment of osteoarthritis	Samumed, LLC (San Diego, CA)
SM04690		Process for preparing N-(5-(3-(7-(3-fluorophenyl)-3H-imidazo[4,5-C]pyridin-2-yl)-1H-indazol-5-y- l)pyridin-3-yl)-3-methylbutanamide	Samumed, LLC (San Diego, CA)
SM04690		Single-dose, ready-to-use injectable formulations	Samumed, LLC (San Diego, CA)
SM04690		Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof	Samumed, LLC (San Diego, CA)
SM04690		Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof	Samumed, LLC (San Diego, CA)

International Patents for SM04690

Drugname	Country	Document Number	Estimated Expiration	Related US Patent
SM04690	Australia	AU2017274350	2036-06-01
SM04690	Brazil	BR112018074725	2036-06-01
SM04690	Canada	CA3026076	2036-06-01
SM04690	Chile	CL2018003423	2036-06-01
SM04690	China	CN109476660	2036-06-01
SM04690	European Patent Office	EP3464285	2036-06-01
SM04690	Israel	IL263362	2036-06-01